Market Overview:
The global gynecological cancer drugs market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of gynecological cancers, rising awareness about early diagnosis and treatment options, and technological advancements in the field of cancer treatment. The global gynecological cancer drugs market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into chemotherapy, targeted therapy, and hormonal therapy. Chemotherapy dominates the global gynecological cancer drugs market owing to its high efficacy in treating various types of cancers. On the basis of application, uterine cancer dominates the global gynecological cancer drugs market followed by ovariancancer and vaginalcancer .
Product Definition:
Gynecological cancer drugs are medicines used to treat cancers of the female reproductive system, including ovarian cancer, uterine cancer, and cervical cancer. Gynecological cancers can be treated with surgery, radiation therapy, chemotherapy or a combination of these treatments. Some gynecological cancers are also treated with hormone therapy.
Chemotherapy:
Chemotherapy is the use of drugs or other substances to treat cancer. Chemotherapy may be used in combination with radiation therapy, surgery, or a combination of both. The most common types of cancers treated with chemotherapy include lung cancer, breast cancer (in women), and leukemia (in men).
The global chemotherapy market size was valued at USD 21 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period.
Targeted Therapy:
Targeted therapy is a type of cancer treatment that attacks and eliminates specific cancer cells. It's majorly used for the treatment of advanced stages of cancers, which cannot be treated with surgery or radiation. Targeted therapy includes drugs, biologics, monoclonal antibodies (mAbs), and small molecule drugs.
Application Insights:
The uterine cancer segment dominated the global market in 2017 owing to increasing incidence rates of this cancer and availability of a number of drugs in the market. According to estimates published by U.S. National Cancer Institute, around 14,070 new cases were reported globally in 2018 and about 5,260 deaths were recorded due to uterine cancer that year.
Ovarian cancer is expected to be the fastest-growing application segment over the forecast period owing to high incidence rates coupled with availability of a number of drugs for treatment purposes such as aromatase inhibitors (AI), anti-androgenic drugs (AD) and gonadotropin releasing hormone analogs (GnRHAs). For instance, according Ovarian Cancer Research Foundation International Inc., an estimated 5230 new cases are anticipated to be diagnosed with ovarian carcinoma worldwide this year along with about 2180 deaths; while around 1090 new cases are likelyto be diagnosed along with about 460 deaths in 2019 respectively.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased R&D investments by them, and high adoption of modern treatment procedures. The gynecological cancer drugs market is expected to witness a rise in demand from emerging economies such as China and India owing to rising awareness about early diagnosis coupled with increasing disposable income levels.
Asia Pacific is anticipated to register lucrative growth over the forecast period owing to growing healthcare expenditure levels in this region along with increasing government initiatives for improving women health care access rates especially across rural areas. Moreover, rising incidence rates of cervical cancer are also contributing towards regional growth due to its early detection methods availability that includes liquid-based cytology screening tests and HPV testing using COVID-19 kits which are now approved by Health Canada under special emergency use authorization (EUA).
Growth Factors:
- Increasing incidence of gynecological cancer
- Growing awareness about gynecological cancer and its treatment options
- Rising demand for better and more effective treatments for gynecological cancers
- Technologically advanced and novel drugs in the pipeline for treating gynecological cancers
- Availability of government funding and support for research on gynecological cancers
Scope Of The Report
Report Attributes
Report Details
Report Title
Gynecological Cancer Drugs Market Research Report
By Type
Chemotherapy, Targeted Therapy, Hormonal Therapy
By Application
Uterine Cancer, Ovarian Cancer, Vaginal Cancer, Cervical Cancer
By Companies
Apotex, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical Industries, Apotex
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Gynecological Cancer Drugs Market Report Segments:
The global Gynecological Cancer Drugs market is segmented on the basis of:
Types
Chemotherapy, Targeted Therapy, Hormonal Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Uterine Cancer, Ovarian Cancer, Vaginal Cancer, Cervical Cancer
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Apotex
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly
- F. Hoffmann-La Roche
- GlaxoSmithKline
- Merck
- Novartis
- Pfizer
- Teva Pharmaceutical Industries
- Apotex
Highlights of The Gynecological Cancer Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy
- Targeted Therapy
- Hormonal Therapy
- By Application:
- Uterine Cancer
- Ovarian Cancer
- Vaginal Cancer
- Cervical Cancer
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gynecological Cancer Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gynecological cancer drugs are medications used to treat cancer that originates in the female reproductive system. These drugs can be used to treat a variety of different types of gynecological cancers, including ovarian, cervical, and uterine cancers. Gynecological cancer drugs can also be used to help prevent further growth or spread of the tumor.
Some of the key players operating in the gynecological cancer drugs market are Apotex, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical Industries, Apotex.
The gynecological cancer drugs market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gynecological Cancer Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Gynecological Cancer Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Gynecological Cancer Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Gynecological Cancer Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Gynecological Cancer Drugs Market Size & Forecast, 2018-2028
4.5.1 Gynecological Cancer Drugs Market Size and Y-o-Y Growth
4.5.2 Gynecological Cancer Drugs Market Absolute $ Opportunity
Chapter 5 Global Gynecological Cancer Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Gynecological Cancer Drugs Market Size Forecast by Type
5.2.1 Chemotherapy
5.2.2 Targeted Therapy
5.2.3 Hormonal Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Gynecological Cancer Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Gynecological Cancer Drugs Market Size Forecast by Applications
6.2.1 Uterine Cancer
6.2.2 Ovarian Cancer
6.2.3 Vaginal Cancer
6.2.4 Cervical Cancer
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gynecological Cancer Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gynecological Cancer Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Gynecological Cancer Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Gynecological Cancer Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Gynecological Cancer Drugs Market Size Forecast by Type
9.6.1 Chemotherapy
9.6.2 Targeted Therapy
9.6.3 Hormonal Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Gynecological Cancer Drugs Market Size Forecast by Applications
9.10.1 Uterine Cancer
9.10.2 Ovarian Cancer
9.10.3 Vaginal Cancer
9.10.4 Cervical Cancer
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Gynecological Cancer Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Gynecological Cancer Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Gynecological Cancer Drugs Market Size Forecast by Type
10.6.1 Chemotherapy
10.6.2 Targeted Therapy
10.6.3 Hormonal Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Gynecological Cancer Drugs Market Size Forecast by Applications
10.10.1 Uterine Cancer
10.10.2 Ovarian Cancer
10.10.3 Vaginal Cancer
10.10.4 Cervical Cancer
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Gynecological Cancer Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Gynecological Cancer Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Gynecological Cancer Drugs Market Size Forecast by Type
11.6.1 Chemotherapy
11.6.2 Targeted Therapy
11.6.3 Hormonal Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Gynecological Cancer Drugs Market Size Forecast by Applications
11.10.1 Uterine Cancer
11.10.2 Ovarian Cancer
11.10.3 Vaginal Cancer
11.10.4 Cervical Cancer
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Gynecological Cancer Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Gynecological Cancer Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Gynecological Cancer Drugs Market Size Forecast by Type
12.6.1 Chemotherapy
12.6.2 Targeted Therapy
12.6.3 Hormonal Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Gynecological Cancer Drugs Market Size Forecast by Applications
12.10.1 Uterine Cancer
12.10.2 Ovarian Cancer
12.10.3 Vaginal Cancer
12.10.4 Cervical Cancer
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Gynecological Cancer Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Gynecological Cancer Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Gynecological Cancer Drugs Market Size Forecast by Type
13.6.1 Chemotherapy
13.6.2 Targeted Therapy
13.6.3 Hormonal Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Gynecological Cancer Drugs Market Size Forecast by Applications
13.10.1 Uterine Cancer
13.10.2 Ovarian Cancer
13.10.3 Vaginal Cancer
13.10.4 Cervical Cancer
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gynecological Cancer Drugs Market: Competitive Dashboard
14.2 Global Gynecological Cancer Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Apotex
14.3.2 AstraZeneca
14.3.3 Bristol-Myers Squibb
14.3.4 Eli Lilly
14.3.5 F. Hoffmann-La Roche
14.3.6 GlaxoSmithKline
14.3.7 Merck
14.3.8 Novartis
14.3.9 Pfizer
14.3.10 Teva Pharmaceutical Industries
14.3.11 Apotex
